Innate shows Bicycle the path for Nectin-4
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
Novartis’s post-Pluvicto plan materialises
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
Lilly buys in another PI3Kα inhibitor
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
SABCS 2024 – Lilly's PI3Kα push is no longer mutation-specific
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
